New findings suggest OrsoBio’s energy-burning approach could enhance tirzepatide’s effects while opening new possibilities for healthy aging.
The next act after GLP-1s? US-based biopharma OrsoBio has a case.
Obesity medicine has few unexpected transformations in recent years. Drugs such as tirzepatide have reshaped expectations around weight loss, helping millions of people achieve results once thought possible only through bariatric surgery. However, as impressive as these therapies have been, researchers are already asking the next question: what comes after appetite suppression?
At this year’s American Diabetes Association Scientific Sessions in New Orleans, OrsoBio presented data that point toward one possible answer. The clinical-stage biotech company unveiled new findings showing that its experimental therapy TLC-6740 may amplify the benefits of tirzepatide, while separate preclinical studies suggest its next-generation candidate, TLC-1180, could influence everything from exercise capacity to cognitive health [1].
Most of today’s blockbuster obesity drugs work by reducing food intake. They help people feel fuller, longer, naturally lowering calorie consumption. OrsoBio is pursuing the other side of the equation. Its therapies belong to a class known as mitochondrial protonophores, compounds designed to increase energy expenditure at the cellular level. OrsoBio’s approach aims to help the body burn more of the fuel it already has.
The company’s headline clinical result came from a 24-week Phase 2a trial evaluating TLC-6740 alongside tirzepatide in people living with obesity but not diabetes.
Participants receiving the combination achieved an additional 4.5% average weight loss compared with those receiving tirzepatide alone. Researchers also reported improvements in insulin sensitivity, liver health and body composition.
Just as importantly, the combination appeared to be well tolerated. According to the company, adverse events were similar to those typically associated with incretin therapies, with no severe adverse events, treatment discontinuations or signs of excessive systemic activity observed in participants receiving TLC-6740. Much like oncology and cardiovascular medicine before it, obesity treatment appears to be moving toward strategies that target multiple biological pathways simultaneously.
“Our clinical findings further support the potential of mitochondrial protonophores as complementary therapies that increase energy expenditure while incretin-based medicines primarily target energy intake,” said Dr Rob Myers, Chief Medical Officer of OrsoBio.
Perhaps the most interesting aspect of OrsoBio’s latest data is that the company is not positioning its therapies as simple weight-loss enhancers.
In preclinical studies, TLC-1180 improved insulin sensitivity across multiple tissues, including the liver, skeletal muscle, heart and adipose tissue. The treated animals also demonstrated improved exercise performance, running longer and faster while maintaining lean mass.
Weight itself has been treated as the primary outcome. Today, researchers are paying closer attention to metabolic resilience: how effectively the body manages energy, maintains muscle, protects cardiovascular health and preserves function as people age. In that context, losing weight is increasingly viewed as only part of the story.
“These new data reinforce our belief that mitochondrial protonophores represent a differentiated therapeutic approach capable of addressing multiple manifestations of obesity-related disease,” said Dr Mani Subramanian, CEO of OrsoBio.
Also, one of the more unexpected findings involved cognition. A separate study found that TLC-1180 partially restored memory and exploratory behavior in mice experiencing obesity-related metabolic dysfunction. Researchers also observed improvements in neuronal activity within brain regions involved in cognition.
The findings remain early and were observed only in animal models. Still, they arrive amid growing evidence that metabolic health and brain health are deeply intertwined. Scientists increasingly recognize obesity as a risk factor not only for diabetes and cardiovascular disease, but also for cognitive decline later in life. The idea that improving metabolic function could help protect the brain has become one of the more intriguing themes emerging from longevity research.
If confirmed in humans, therapies that target metabolism could potentially influence a much broader range of age-related conditions than previously imagined.
Longevity researchers have long argued that metabolic dysfunction sits near the center of many chronic diseases associated with aging. Poor glucose control, excess visceral fat, declining cardiovascular function and cognitive impairment often appear together, reinforcing one another over time.
What makes OrsoBio’s latest findings noteworthy is not simply the additional weight loss achieved alongside tirzepatide, but the suggestion that targeting cellular energy use may affect multiple systems at once. That remains a hypothesis rather than a proven outcome. TLC-1180 is only beginning human testing, and larger clinical studies will be needed to determine whether the broad benefits seen in preclinical models translate to people. Still, the data offer a glimpse of the next chapter being defined by helping the body manage energy better.
If the question is what comes after GLP-1s, OrsoBio’s latest results suggest the industry may already be writing the next one.
